Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Clinical trial NCT02758587 · UNKNOWN

Trial details

NCT number: NCT02758587
Sponsor: NHS Greater Glasgow and Clyde
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-small-cell Lung Mesothelioma Pancreatic Neoplasms

Start date: 2017-07-04
Primary completion: 2019-05-01
Enrollment: 59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.